Noriyuki Kasahara - 23 Sep 2022 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role: Director
Signature: /s/ August J. Moretti, Attorney-in-Fact for Noriyuki Kasahara
Issuer symbol: FDMT
Transactions as of: 23 Sep 2022
Net transactions value: $0
Form type: 4
Filing time: 27 Sep 2022, 17:08:46 UTC
Next filing: 25 May 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FDMT	Stock Option (Right to Buy)	Award	$0	+45,000		$0.000000	45,000	23 Sep 2022	Common Stock	45,000	$8.06	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option vests and becomes exercisable with respect to 1/3 of the total shares on September 23, 2023 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on September 23, 2025. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

Content

The stock option vests and becomes exercisable with respect to 1/3 of the total shares on September 23, 2023 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on September 23, 2025. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).